Merck to Hold Third-Quarter 2021 Sales and Earnings Conference Call on October 28
28 September 2021 - 8:45PM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, will hold its third-quarter 2021 sales and earnings
conference call with institutional investors and analysts at 8:00
a.m. EDT on Thursday, October 28. During the call, company
executives will provide an overview of Merck’s performance for the
quarter and outlook.
Investors, journalists and the general public may access a live
audio webcast of the call on Merck’s website at
https://www.merck.com/investor-relations/events-and-presentations/.
A replay of the webcast, along with the sales and earnings news
release and supplemental financial disclosures and slides
highlighting the results, will be available at www.merck.com.
Institutional investors and analysts can participate in the call
by dialing (833) 353-0277 or (469) 886-1947 and using ID code
number 6768456. Members of the media are invited to monitor the
call by dialing (833) 353-0277 or (469) 886-1947 and using ID code
number 6768456. Journalists who wish to ask questions are requested
to contact a member of Merck’s Media Relations team at the
conclusion of the call.
About Merck
For over 130 years, Merck, known as MSD outside of the United
States and Canada, has been inventing for life, bringing forward
medicines and vaccines for many of the world’s most challenging
diseases in pursuit of our mission to save and improve lives. We
demonstrate our commitment to patients and population health by
increasing access to health care through far-reaching policies,
programs and partnerships. Today, Merck continues to be at the
forefront of research to prevent and treat diseases that threaten
people and animals – including cancer, infectious diseases such as
HIV and Ebola, and emerging animal diseases – as we aspire to be
the premier research-intensive biopharmaceutical company in the
world. For more information, visit www.merck.com and connect with
us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the global outbreak of novel coronavirus disease
(COVID-19); the impact of pharmaceutical industry regulation and
health care legislation in the United States and internationally;
global trends toward health care cost containment; technological
advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining
regulatory approval; the company’s ability to accurately predict
future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and
other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2020
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210928005210/en/
Media: Patrick Ryan (973) 275-7075 Melissa Moody (215) 407-3536
Investor: Peter Dannenbaum (908) 740-1037 Raychel Kruper (908)
740-2107
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024